Upcoming event

ESOU21: Brilliant updates on the most recent developments in renal cell carcinoma

By Dr. Umberto Capitanio

The 18th Meeting of the EAU Section of Oncological Urology (ESOU 21) was held from 29 to 31 January 2021 in a virtual fashion. Brilliant and interesting updates on the most recent developments in the setting of organ-confined, locally advanced, and metastatic renal cell carcinoma (RCC) were provided.

On Friday, the “Renal cancer I: localised session” was chaired by Dr. Alcaraz and Dr. Volpe. Important technical aspects in renal surgery were analysed: preparation of the renal hilum, the use of fluorescence, the role of ischemia vs. no ischemia, and resection techniques. Dr. Mir presented an interesting clinical case of a large RCC and the subsequent potential therapeutical strategies (radical surgery vs. nephron-sparing surgery).

On Saturday, the joint ESOU and European Urology Oncology (EUO) “Renal cancer II – locally advanced and metastatic” session was chaired by Dr. Albiges, Dr. Grimm, Dr. Mejean, Dr. Powles, and Dr. Capitanio. The main topics were systemic treatment of metastatic RCC and the surgical and perioperative challenges of large renal tumours, with a specific focus on vena cava and lymph nodes management.

On Sunday, the session “Renal cancer III: Advanced and metastatic renal cancer” was chaired by Dr. Bex and Prof. Ravaud. Dr. Moch presented very interesting data regarding the histological classification and the immunophenotyping of renal tumours. Dr. Bex updated the audience on the role of cytoreductive nephrectomy. Dr. Ravaud analysed whether every metastatic patient needs immunotherapy in a first-line setting.

Finally, Dr. Thibault presented a clinical case of advanced and metastatic RCC in a session which was moderated by Dr. Grimm, Dr. Albiges, Prof. Bex, and Dr. Ravaud.

During the joint session of the ESOU, EAU Section of Urological Research (ESUR), EAU Section of Uropathology (ESUP), and European Urology Oncology, Dr. Campi gave us a brilliant overview of the “must-read papers in onco-urology 2020.” He reviewed 17 uro-oncological journals with a total of 298 RCC papers which were categorized into seven different topics. Here is a list of must-read 2020 papers in the field of RCC:

A.Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. Rossi SH, Blick C, Handforth C, Brown JE, Stewart GD; Renal Cancer Gap Analysis Collaborative.

B. Predicting intra-operative and postoperative consequential events using machine-learning techniques in patients undergoing robot-assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. Bhandari M, Nallabasannagari AR, Reddiboina M, Porter JR, Jeong W, Mottrie A, Dasgupta P, Challacombe B, Abaza R, Rha KH, Parekh DJ, Ahlawat R, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Buffi NM, Sivaraman A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Meyyazhgan KR, Patil P, Menon M, Rogers C.

C. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Porpiglia F, Checcucci E, Amparore D, Piramide F, Volpi G, Granato S, Verri P, Manfredi M, Bellin A, Piazzolla P, Autorino R, Morra I, Fiori C, Mottrie A.

D. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson EO, Lam TB, Marconi L, Fernandéz-Pello S, Nisen H, Meijer RP, Volpe A, Ljungberg B, Klatte T, Dabestani S, Bex A.

E. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. Jamil ML, Keeley J, Sood A, Dalela D, Arora S, Peabody JO, Trinh QD, Menon M, Rogers CG, Abdollah F.

F. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo

G. Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. Metcalf MR, Cheaib JG, Biles MJ, Patel HD, Peña VN, Chang P, Wagner AA, McKiernan JM, Pierorazio PM.

H. Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Ball MW, An JY, Gomella PT, Gautam R, Ricketts CJ, Vocke CD, Schmidt LS, Merino MJ, Srinivasan R, Malayeri AA, Metwalli AR, Linehan WM.

I. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG.

J. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L.

For more ESOU21 webcasts, please visit the ESOU21 resource centre.